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Trafﬁckingsolic heteromeric Golgi complex constituted of 8 subunits (Cog1 to Cog8) and
involved in retrograde vesicular Golgi trafﬁcking. The involvement of this complex in glycosylation and more
speciﬁcally in Golgi glycosyltransferases localization has been highlighted with the discovery of COG subunit
deﬁciencies leading to CDG (Congenital Disorders of Glycosylation), a group of inherited disorders of
glycosylation. To date, many COG deﬁcient CDG patients have been discovered and this article reviews the
birth and rise of this group of defects. The architecture of the COG complex and its cellular functions in Golgi
trafﬁcking and Golgi glycosylation are discussed.
© 2008 Elsevier B.V. All rights reserved.1. Factors regulating glycosylation in the Golgi apparatus
Most cell surface and secreted macromolecules carry sugar
chains (also called glycans or oligosaccharides) that were initially
attached or modiﬁed in the Golgi apparatus. The Golgi apparatus
has two main roles. The ﬁrst one is the post-translational modiﬁ-
cation of newly synthesized proteins and lipids as they pass through
this organelle. The second is to target the proteins and lipids to the
right compartments (e.g. cell surface, lysosomes, endosomes).
Despite other cellular functions, the Golgi compartment can be
considered as the organelle achieving the correct terminal glycosy-
lation of proteins and lipids. Many types of glycosylation encom-
passing N-glycans, O-glycans and glycosaminoglycans are produced.
In term of structures, the Golgi apparatus allows an amazing
structural diversity of glycans. To achieve this diversity, the bio-
synthesis of the sugar chain must be tightly regulated and
deﬁciencies lead to a group of rare genetic diseases called CDG for
Congenital Disorders of Glycosylation. Identiﬁed for the ﬁrst time in
1980 by Jaeken and collaborators, more than 20 new deﬁciencies
have been identiﬁed so far. Based on the Isoelectric Focusing pattern
of serum transferrin (IEF-Tf), two groups of CDG can be distin-
guished. Types I (CDG-I), associated with an absence of one or two
glycans on transferrin, result in defects of the oligosaccharide
precursor or its subsequent transfer onto a nascent protein in the ER
lumen. At the opposite, types II (CDG-II), harboring a variable
increase of the undersialylated forms of transferrin, indicates defects
in the processing of the glycan chains occurring mainly in the Golgi
apparatus [1].ll rights reserved.The glycosylation reaction not only requires many proteins and
enzymes but also an adequate environment. Constructed in an
ordered sequential manner, biosynthesis of glycan chains in the
Golgi apparatus involves a subset of speciﬁc glycosyltransferases,
glycosidases and activated sugar nucleotides. To summarize, we
could say that the complexity of oligosaccharide structures observed
on secreted and/or membrane glycoproteins is the result of a
dynamic process depending on the activities of glycosyltransferases
and remodeling glycosidases. In reality, the Golgi glycosylation
process is much more complicated and many other factors can
affect and lead to variations in the glycan structures (Fig. 1). Before
introducing the COG complex as trafﬁcking defects, we summarize a
few other factors that can also affect glycosylation in the Golgi.
1.1. Expression of Golgi glycosyltransferases, glycosidases and nucleotide
sugar transporters
Mutations in genes coding for Golgi glycosyltransferases, glyco-
sidases or nucleotide sugar transporters are the ﬁrst cause of
abnormal glycosylation. Most often; these mutations affect the
mRNA stability and/or the biochemical activity of the protein. This
is what is observed in most of the identiﬁed CDG-II in particularly
the CDG-IIa, IIb, IIc, IId and IIf [2–6].
1.2. Activation of cytosolic monosaccharides into dinucleotide
sugar donors
Defects in enzymes involved in the biosynthesis of activated sugars
can also have dramatic effects on Golgi glycosylation reaction by
affecting the steady-state concentration of available nucleotide sugars.
Another critical parameter concerns the topology of the different
Fig.1.Golgi glycosylation reaction. Dinucleotide sugars are synthesized in the cytosol
and then transported by speciﬁc nucleotide sugar transporters (NT) into the Golgi
lumen. These transporters are antiporters that mediate exchange with the
corresponding mononucleotides. The monosaccharide can be then used by Golgi
glycosyltransferases (GT). The enzymatic reaction requires an adequate environment
in terms of luminal concentrations of H+, Mn2+, Mg2+ and inorganic phosphate
(Pi). The XDP produced is converted to XMP and Pi by a nucleoside diphosphatase
activity.
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glycosyltransferases are made in the cytosol (except for CMP-NeuAc
which is synthesized in the nucleus) while the glycosylation reaction
is carried out into the Golgi lumen. A family of speciﬁc nucleotide
transporters will achieve this function by pumping the activated
sugars from the cytosol into the Golgi compartment. Up to now, two
deﬁciencies in nucleotide sugar transporters have been reported: one
in the GDP-Fucose transporter leading to CDG-IIc and one in the CMP-
NeuAc leading to CDG-IIf [4,6].
These transporters are antiporters that mediate exchange with the
corresponding mononucleotides (Fig. 1). This implies in the Golgi
lumen a nucleoside diphosphatase activity that breaking down UDP
and GDP into UMP and GMP. A Golgi GDPase encoded by the GDA1
gene has been cloned in yeast in 1993 by Abeijon et al. [7] and 6 years
later, another gene, homologous to GDA1 and named YND1 was
cloned [8]. Interestingly, both gda1 and ynd1 null mutants are
defective in Golgi glycosylation [8]. It has indeed been reported that
the removal of these mononucleotides is crucial and can inhibit the
activities of Golgi glycosyltransferases.
1.3. Presence of divalent cations
Most of the Golgi glycosyltransferases require divalent cations as
Mn2+ and/or Mg2+ for their activity. As an example, the β1,4-galac-
tosyltransferase I, which functions as the catalytic component of the
lactose synthase and which is involved in the glycosylation of
glycoproteins, has an absolute requirement for Mn2+ [9].
1.4. pH of the Golgi compartment
The luminal pH of the organelles along the secretory pathway
is different and becomes more acidic as the exocytotic or endo-
cytotic pathways approach their destination [10]. The regulation of
the luminal acidity is selectively achieved by a vacuolar-type H+-
ATPase. For the Golgi glycosylation reaction, the requirement of an
adequate pH in the Golgi lumen has recently been highlighted in a
human disease with a deﬁcient V-ATPase activity. [11].1.5. Correct Golgi localization
Golgi glycosyltransferases are all type II transmembrane pro-
teins catalyzing distinct glycosylation reactions and found restricted
to a subset of Golgi cisternae. To achieve a correct glycosylation,
not only the localization of the GT is crucial but also the
localization of the nucleotide sugar transporters. The Golgi
glycosylation reaction indeed requires that the dinucleotide sugar
donors are located in the same compartment than the GT that will
use them. The precise molecular mechanisms responsible for the
non uniform distribution of GT and nucleotide sugar transporters
are not completely understood. Up to now, the idea is that GT, as
presumably the nucleotide sugar transporters, can retrieve from
late Golgi cisternae back to early cisternae by retrograde trafﬁcking.
The involvement of the retrograde trafﬁcking in the steady state
distribution of Golgi GT has recently been illustrated by the
discovery of a group of inherited disorders of glycosylation with
deﬁciencies in the Conserved Oligomeric Golgi (COG) complex
subunits.
2. The COG complex
The identiﬁcation and characterization of the ﬁrst COG mutant
cells began in 1981 with the description of two CHO cell mutants
(called ldlB and ldlC), both deﬁcient in the low density lipoprotein
receptor [12]. In these cells, authors demonstrated that Golgi
cisternae were dilated and that the synthesis of virtually all N- and
O-linked glycoproteins and of the major glycolipid oligosaccharides
was abnormal [13]. The observed affected stability and thus very low
LDL receptor activity was explained by the aberrant glycosylation of
the LDL receptors in ldlB and ldlC cells. While secretory and
endocytic pathways have been shown to be normal in these cells,
the Golgi glycosylation deﬁciencies led to the suggestion that the
proteins that were deﬁcient in ldlB and ldlC could inﬂuence the
localization, stability and/or activity of many Golgi glycosylation
enzymes. The LDLB and LDLC genes were cloned in 1999 and 1994
respectively [14,15]. The COG complex was not yet known but it was
already demonstrated that these proteins were components of a
950 kDa complex (ldlc complex) and found that ldlB was required
for the normal assembly and stability of this complex [15]. In other
studies, the “ldlc complex” was characterized as the Sec34/35 com-
plex [16] and the GTC-90 complex, a 13S hetero-oligomeric protein
complex able to stimulate in vitro Golgi transport [17]. In fact,
diverse names were given to a common complex which is called
since 2002: the COG complex [18].
The COG complex is an octa heteromeric complex constituted of
8 subunits (Cog1 to Cog8) arranged in two lobes, lobe A (Cog1–4)
and lobe B (Cog5–8) [18,19]. An important amount of work has
been done to delineate the subunit interaction map of the COG
complex. By using different approaches, several different models
have been proposed.
Using an in-vitro translation system, Loh and Hong proposed
that Cog4 would play the central subunit connecting the two lobes
together (Fig. 2, model 1) [20]. This model is in accordance with
the two-lobed model but differs signiﬁcantly from the models
proposed by Fotso et al. [21] and Ungar et al. [22]. In yeast cells, the
Cog1 subunit has been shown to be essential for the interaction of
the two lobes (Fig. 2, model 2) [21]. The third model, proposed by
Ungar et al., suggests a direct interaction of both Cog8 with Cog1
and Cog5–7 (Fig. 2, model 3) [22]. The last model presented by Oka
et al. provide strong support for the model 3 [23]. Indeed, in this
study, direct in-vivo interaction of Cog8 with the lobe A (Cog1–4)
has been reported. Altogether, from these different models, it
clearly appears that besides the full COG complex composed of the
Cog1 to Cog8 subunit, subcomplexes can also be formed (Cog1+8,
Cog2–4, (Cog1–4)+8, Cog5–7 and (Cog5–7)+8. It will be important
Fig. 2. Different models of COG architecture. Numbers represent COG subunits.
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functions of the different subcomplexes.
3. COG and glycosylation
As mentioned earlier, the signiﬁcant impact of COG defects on
glycosylation was known since 1986 [13]. The similarity of the
glycosylation defects found in the ldlB (COG1 knockout) and ldlC
(COG2 knockout) cells with those found in some unsolved CDG-II
patients, led to the identiﬁcation by the group of H. Freeze in 2004
of the ﬁrst case of Cog7 deﬁcient CDG patient [24]. The link between
inherited deﬁciencies in intracellular protein trafﬁcking and human
diseases that alter glycosylation was done. People thus interested in
CDG began to be interested by the ﬁeld of intravesicular Golgi
trafﬁcking. To date, other COG deﬁcient CDG patients with different
affected COG subunits have been identiﬁed. This will be reviewed
later in this article.
The impact of COG defects on Golgi glycosylation resides in the
cellular function of COG in controlling the intracellular trafﬁcking
and/or stability of a variety of Golgi-associated glycosylation
enzymes [24–30]. For example, a subset of 7 Golgi type II pro-
teins, (called GEARs) including the Golgi mannosidase II, was
found mislocalized and/or unstable in ldlB and ldlC CHO deﬁcient
cells lines [23]. From other recent studies, we now know that
many other proteins either involved in vesicular Golgi trafﬁcking
or Golgi glycosylation are affected by COG deﬁciencies. Among
these proteins, ﬁve Golgi glycosylation enzymes, including the
Golgi mannosidase II (MannII), the β1,4-galactosyltransferase I
(GalT), the β1,3-galactosyltransferase (core1 GalT), the sialyltrans-
ferase hST3Gal1 and the GlcNAc transferase I (GlcNAcTI), are
mislocalized and/or abnormally rapidly degraded in COG-deﬁcient
cells [24–30]. Such effects on yeast COG mutant cells have also
been reported for two Golgi mannosyltransferases, Och1p and
Mn1p [31].
4. COG and trafﬁcking
Little is known about the Golgi localization of Golgi glycosyl-
transferases or how they are retrieved from distal compartments
back to their site of function. The involvement of the COG complex
in trafﬁcking and/or stability of Golgi enzymes may give us a start
of an answer. Substantial evidence tends to suggest that the COGcomplex is involved in retrograde membrane trafﬁcking of Golgi
resident proteins [24,29,32]. If this model is correct, mutations in
subunits of the COG complex would lead thus to a physical sepa-
ration of speciﬁc Golgi enzymes from the molecules to be glyco-
sylated passing through the Golgi via the anterograde pathway. This
is supported by the fact that, in both yeast and mammalian cells,
deﬁciencies in individual COG subunits can lead to accumulation of
vesicles [29,32,33]. Additional evidence is the presence of GEARs
and other glycosylation enzymes in COG-complex-dependent (CCD)
vesicles. Indeed, when levels of Cog3 in HeLa cells are reduced
by RNAi, GlcNAcTI and MannII, are found in CCD vesicles [32]. In
order to explain the cellular function of the COG complex in the
Golgi localization glycosyltransferases, Lupashin and collaborators
presented a model where COG would play a role by constantly
retrieving Golgi proteins from distal compartments back to their
site of function (Fig. 3). In case of COG defects, the Golgi enzymes
would thus in vesicles unable to deliver their content to speciﬁc
cisternae. Altogether, this means that COG would act as a tethering
complex in rder to tether vesicles that retrieve from distal Golgi
compartments.
5. Clinical presentation of COG deﬁcient CDG patients
5.1. COG7
In 2004, Wu et al. described the ﬁrst patients (two siblings)
with a deﬁciency in the Cog7 subunit [24]. Born to healthy con-
sanguineous North African parents, the two children died either 5
or 10 weeks after birth. The clinical picture is severe and the
siblings displayed perinatal asphyxia, generalized hypotonia, hepa-
tosplenomegaly, dysmorphic features with loose, micrognathia,
short neck and wrinkled skin. Severe epileptic episodes were
observed and the children died from recurrent infections or cardiac
insufﬁciency [24].
Up to date, six additional patients from four different families were
identiﬁed with a consistent clinical phenotype observed in the ﬁrst
patients [28,34]. The phenotypic features of the four patients are
intrauterine growth retardation, pronounced congenital hypotonia
with adducted thumbs, dysmorphic features (except for the last),
progressive microcephaly, failure to thrive, feeding difﬁculties and/or
intestinal pseudoobstruction, episodes of severe hyperthermia and
cardiac anomalies in most of the patients.
Fig. 3.Model explaining how COG functions in the Golgi glycosyltransferases localization. The COG complex acts as a tethering complex in order to tether vesicles containing Golgi
glycosylation enzymes that retrieve from distal Golgi compartments.
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intronic mutation (c.169+4ANC). This mutation disrupts the splice
donor site and activates at least two different cryptic splice sites.
During the preparation of this report, Zeevaert and colleagues
reported a new Cog7 deﬁcient patient (submitted). From a clinical
point of view, this patient shares common features with the other
Cog7 deﬁcient patients except for growth retardation and dysmorphic
features that were absent in this patient (Table 1). The mutation,
which differs from the one found in the six other patients, is a
homozygous intronic mutation (c.170−7ANG) which creates a newTable 1










Ethnicity Morocco Morocco Morocco Tunisia
Consanguinity + + + +
Lethality in the ﬁrst year + + + +
Short length at birth + + + +
Microcephaly at birth + – + +
Progressive microcephaly + + + +
Growth retardation + + + +
Micrognathia + + + +
Small mouth, retrognathia + + + +
Short neck + + + +
Wrinkled, loose, soft skin + + + +
Hypotonia + + + +
Overlapping, long ﬁngers + + + +
Failure to thrive + + + +
Convulsions + – + +
Cerebral atrophy + + + +
Periods with hyperthermia + + + +
Feeding problems/pseudoobstruction + + – +
Failure to thrive + + + +
CK elevations in blood + + + ND
Liver enzyme elevations +/– +/– + +splice acceptor. At the protein level, Ala–Thr insertion at amino acid
positions 56–57 was observed (p.56–57insAT).
5.2. COG1
Up to now, this is the only one CDG patient identiﬁed with a COG1
deﬁciency. The patient described here is a girl, born from con-
sanguineous and healthy parents. She had feeding problems since
birth and failure to thrive by the end of the ﬁrst month. Clinical














Tunisia Morocco Morocco Portugal Spain ND
+ + + + + ND
+ + – (17mo) – – –
+ ND – – – –
+ + – – – –
+ ND + + + ND
+ + + + + +
+ + – – – ND
+ + ND – + ND
+ + ND – + ND
+ ND ND – – ND
+ + + + + +
+ + ND – + ND
+ + + + + +
ND + ND – + ND
+ + + + + +
+ + + – – ND
ND + + + + +
ND + + + + +
ND – ND ND + ND
+ +/– +/– + + ND
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feet, straightened bitemporal space, and antimongoloid eyelids. There
was no hepatosplenomegaly. At the age of 7 months, she developed
growth retardation with a rhizomelic short stature. Growth and head
circumference were below the ﬁfth percentile. A progressive micro-
cephaly and enlarged liver were registered. Brain MRI indicated only
a slight cerebral and cerebellar atrophy.
The mutation is a homozygous insertion of a single nucleotide
(c.2659–2660insC). This mutation leads to a premature stop codon at
the position 900 and thus results in the presence of 12 missense
residues and the lack of the C-terminal 80 amino acids.
5.3. COG8
Currently, two patients were described with a COG8 deﬁciency
[26,27].
The ﬁrst one is a Spanish girl born of consanguineous parents.
While the neonatal period and early infancywere normal, at the age of
6 months she presented with an acute encephalopathy and loss of
psychomotor abilities, hypotonia, alternating esotropia, pseudo-ptosis,
and mental retardation. She later developed a cerebellar syndrome
with prominent ataxia and action myoclonus. Brain magnetic
resonance imaging (MRI) showed cerebellar atrophy at the age of
22months. At 8 years of age, she showedminor development progress
developing simple language and understanding. She also presented
with oculomotor apraxia and polyneuropaty of the lower limbs.
The second patient showed hypotonia with poor head control and
he did not reach for objects. At 8.5 years, he is severely retarded with
no speech, nor any bowel or bladder control. He presents striking
lack of muscle from all areas, resembling severe malnutrition. In
comparison with the other COG8 patient, the clinical features over-
lap except that this patient does not present dysmorphic features. A
homozygous nonsense mutation was found (c.1611CNG) in the
Spanish patient thus resulting in the lack of 76 C-terminal amino
acids [26].
In the second COG8 deﬁcient patient, two heterozygous mutations
were identiﬁed, one splice mutation IVS3+1GNA (c.560+1GNA) and
a two basepairs deletion 1687–1688delTT in exon5. At the protein
level, the mutation shortens the protein by 306 C-terminal amino
acids while the second mutation truncates the last 47 C-terminal
amino acids of the protein [27].
6. Biochemical features
6.1. N- and O-glycosylation deﬁciencies
All COG deﬁcient CDG patients found so far exhibit both N- and
O-glycosylation deﬁciencies [24–27]. This was mainly shown either
by mass spectrometry analysis or by the use of lectins such as PNA
for the identiﬁcation of core 1 O-glycan deﬁciencies. Regarding the
N-glycosylation, analysis of total serum N-glycans of COG-deﬁcient
CDG patients' demonstrated an overall decrease in sialylation and
galactosylation with however, differences in the amount of oligo-
saccharides according to the affected Cog subunits. For example, the
percentage of agalactosylated structures strongly depends on the
affected COG subunits. This observation is different for the core1 O-
glycosylation where only the sialylation was shown to be affected
[24–27]. At the cellular level, the enzymes responsible in the
appearance of aberrant N- and O-glycan structures were shown to
be unstable. Mutation of Cog7p resulted in signiﬁcant reduced
activities of nucleotide-sugar transporters (CMP-Sia and UDP-Gal)
and glycosyltransferases (Core1 GalT and ST3Gal-I) of the Golgi
[24,27]. There was also reduced retrograde trafﬁcking for ST3Gal-I in
COG7 mutant ﬁbroblast compared to control cells [24]. Mutation of
Cog1p led to a decrease in MannII and GalT while mutation of Cog8p
shown only a slight GalT decrease [25,26]. Compared to control cells,reduced PNA staining in respectively Cog1, Cog7 and Cog8 deﬁcient
cells led to suggest that hST3Gal1 is also affected [24–27].
6.2. COG architecture
The COG deﬁcient CDG patients were very useful to better
understand the COG subunit architecture and conﬁrm the bi-lobed
organization of the COG complex as described by Ungar and
coworkers. In all COG deﬁcient CDG patients, COG protein instability
was associated with reductions in one or many other COG subunits. In
most cases, the decrease in one COG subunit is associated with the
instability of the other COG subunits belonging to the same lobe.
Mutation in Cog7p leads to an instability on the entire lobe B and
especially of the Cog5p which was undetectable. Mutation in Cog8p
leadsmainly to an instability of the lobeB andmutation in Cog1p leads
also to an instability of the lobeA. However, in speciﬁc COG deﬁcient
patients, an instability of COG subunit belonging to the opposite lobe
can be observed. This is the case of the Cog1 patient where an insta-
bility of the Cog8 subunit and also the Cog8 patients where in both the
Cog1p was decreased. The reciprocal instabilities in these cells of
either Cog1 or Cog8 supported the idea that Cog1 and Cog8 were in
direct physical interaction. Thanks to the truncated Cog1 and Cog8 in
deﬁcient patients, we demonstrated that the C-termini of both Cog8
and Cog1were required for the formation of a stable complex and thus
connect the two lobes together.
6.3. BFA delay
The assessment of a trafﬁcking defect in COG deﬁcient patientswas
investigated by the use BFA (Brefelﬁn A) which is a selective inhibitor
of the GTP-exchange factor Arf1 (ADP-ribosylation factor 1) [35]. This
causes the redistribution of Golgi proteins to the ER via retrograde
transport. By taking the Golgi-mannosidase II as a Golgi marker, a
more or less signiﬁcant delay redistribution of the Golgi mannosidase
II could be observed in the different COG deﬁcient CDG patients
[26,27,30]. This observation is again in favor with a role of the COG
complex in the retrograde trafﬁcking of Golgi enzymes.
7. Diagnosis
The COG deﬁcient CDG patients present a new sub-group of CDG-II
patients and it is anticipated that in the coming years, this sub-group
will be further expand. The remaining question is: how can we
identify them? From this review, four parameters can be checked:
7.1. The clinical features
Even if the number of COG deﬁcient CDG patients is too limited to
draw any ﬁrm conclusions, general characteristics like growth
retardation, failure to thrive, dysmorphic features, microcephaly,
hypotonia, feeding problems and cerebellar atrophy are good indicator
to investigate COG deﬁciencies [36].
7.2. COG subunits stability
The instability of one or several COG subunits in COG deﬁcient CDG
patients is also a general characteristic of these patients. This can be
checked quite easily by western blot by using COG subunits anti-
bodies. However for themoment, only two antibodies directed against
Cog1 and Cog7 are commercially available.
7.3. The N- and O-glycosylation deﬁciencies
Given that theCOGcomplex is involved in thevesicle-mediatedGolgi
retrograde trafﬁcking, Golgi enzymes involved in both N- and O-
glycosylation are affectedbyCOGdeﬁciencies. This canbecheckedeither
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method to diagnose both N- and O-glycosylation deﬁciencies is still
the IEF of serum transferrin and serum ApoC-III. ApoC-III is a plasma
glycoprotein containing a unique core 1 mucin-type O-glycan. Based
on the same concept than transferrin IEF, several isoforms of ApoC-III
can be separated by IEF according to the number of sialic acid residue
attached to the O-glycan [37]. However, only core 1 mucin type O-
glycan deﬁciencies can be picked up with this method which is a
limitation in case of other O-glycosylation defects. In conclusion,
even if these tests are helpful, further conﬁrmation of both N- and O-
glycosylation defects should be obtained by my mass spectrometry
analysis.
7.4. BFA delay
The use of Brefeldin A (BFA) in CDG patient's ﬁbroblasts can be
done as a diagnostic test to pinpoint patients with vesicular Golgi
defects. Upon BFA treatment, extensive transport of Golgi proteins to
the ER is mediated by growth of Golgi tubules. In case of deﬁcient
proteins in retrograde trafﬁcking, a delay in the redistribution of Golgi
proteins to the ER is observed. Since the process of BFA action is
reversible, the anterograde trafﬁcking can also be checked after
treatment and washout of the BFA [35]. In that case, delays of reas-
sembly of the Golgi compartment during BFA washout can provide
precious information on potential anterograde defects.
8. Conclusion
The COG story emerged 4 years ago, when a Cog7 deﬁcient patient
was identiﬁed. To the CDG research community, deﬁciencies in
vesicular Golgi proteins as a cause of glycosylation abnormalities led
to a complete open new ﬁeld of investigations. Ten patients with COG
deﬁciencies were discovered and published to date, and it is highly
expected that other COG deﬁcient CDG patients will be further
identiﬁed in coming years and that, eventually, defects in all COG
subunits will be found.
The treatment of these patients is unfortunately unavailable but a
better understanding of the regulatory mechanisms of Golgi glycosy-
lation is a prerequisite to pinpoint other unsolved CDG-II patients and
be able in the future to offer to the parents, prenatal diagnosis.
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